Intravenous methylprednisolone pulse as a treatment for hospitalised severe COVID-19 patients: results from a randomised controlled clinical trial

Edalatifard, Maryam; Akhtari, Maryam; Salehi, Mohammadreza; Naderi, Zohre; Jamshidi, Ahmadreza; Mostafaei, Shayan; Reza Najafizadeh, Seyed; Farhadi, Elham; Jalili, Nooshin; Esfahani, Masoud; Rahimi, Besharat; Kazemzadeh, Hossein; Mahmoodi Aliabadi, Maedeh; Ghazanfari, Tooba; Sattarian, Mohammadreza; Ebrahimi Louyeh, Hourvash; Reza Raeeskarami, Seyed; Jamalimoghadamsiahkali, Saeidreza; Khajavirad, Nasim; Mahmoudi, Mahdi; Rostamian, Abdolrahman

doi:10.1183/13993003.02808-2020

Public

Intravenous methylprednisolone pulse as a treatment for hospitalised severe COVID-19 patients: results from a randomised controlled clinical trial

Published in European Respiratory Journal • Sep 17, 2020

Authors:

Maryam Edalatifard

Maryam Akhtari

Mohammadreza Salehi

Abstract

Introduction There are no determined treatment agents for severe COVID-19. It is suggested that methylprednisolone, as an immunosuppressive treatment, can reduce the inflammation of the respiratory system in COVID-19 patients. Methods We conducted a single-blind, randomised controlled clinical trial...

Subject

Methylprednisolone

Medicine

Coronavirus disease 2019 (COVID-19)

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!